CN103562390B - 用于细菌的多顺反子表达系统 - Google Patents
用于细菌的多顺反子表达系统 Download PDFInfo
- Publication number
- CN103562390B CN103562390B CN201280026763.2A CN201280026763A CN103562390B CN 103562390 B CN103562390 B CN 103562390B CN 201280026763 A CN201280026763 A CN 201280026763A CN 103562390 B CN103562390 B CN 103562390B
- Authority
- CN
- China
- Prior art keywords
- gene
- endogenous
- genes
- gram
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710467009.7A CN107267546B (zh) | 2011-06-01 | 2012-06-01 | 用于细菌的多顺反子表达系统 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11168495.7 | 2011-06-01 | ||
| EP11168495 | 2011-06-01 | ||
| EP11173588 | 2011-07-12 | ||
| EP11173588.2 | 2011-07-12 | ||
| PCT/EP2012/060431 WO2012164083A1 (en) | 2011-06-01 | 2012-06-01 | Polycistronic expression system for bacteria |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710467009.7A Division CN107267546B (zh) | 2011-06-01 | 2012-06-01 | 用于细菌的多顺反子表达系统 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103562390A CN103562390A (zh) | 2014-02-05 |
| CN103562390B true CN103562390B (zh) | 2017-07-18 |
Family
ID=46354175
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201280026763.2A Expired - Fee Related CN103562390B (zh) | 2011-06-01 | 2012-06-01 | 用于细菌的多顺反子表达系统 |
| CN201710467009.7A Expired - Fee Related CN107267546B (zh) | 2011-06-01 | 2012-06-01 | 用于细菌的多顺反子表达系统 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710467009.7A Expired - Fee Related CN107267546B (zh) | 2011-06-01 | 2012-06-01 | 用于细菌的多顺反子表达系统 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US9920324B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2714912B1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP6175428B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102066292B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN103562390B (cg-RX-API-DMAC7.html) |
| AU (2) | AU2012264589B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112013030824A8 (cg-RX-API-DMAC7.html) |
| CA (2) | CA2837634C (cg-RX-API-DMAC7.html) |
| DK (1) | DK2714912T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2676877T3 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE039577T2 (cg-RX-API-DMAC7.html) |
| RU (2) | RU2644346C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012164083A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2714912B1 (en) | 2011-06-01 | 2018-05-02 | Intrexon Actobiotics NV | Polycistronic expression system for bacteria |
| US9593339B1 (en) * | 2013-02-14 | 2017-03-14 | David Gordon Bermudes | Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment |
| EP3034610A1 (en) * | 2013-08-13 | 2016-06-22 | The Kitasato Institute | Novel terpenoid compound and method for producing same |
| ES2884948T3 (es) | 2014-12-03 | 2021-12-13 | Azusapharma Sciences Inc | Plásmido de coexpresión |
| EP3237622B1 (en) | 2014-12-23 | 2021-02-24 | Ilya Pharma AB | Methods for wound healing |
| AU2016261279B2 (en) | 2015-05-10 | 2020-12-10 | Ventana Medical Systems, Inc. | Compositions and methods for simultaneous inactivation of alkaline phosphatase and peroxidase enzymes during automated multiplex tissue staining assays |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| JP7292877B2 (ja) | 2016-01-14 | 2023-06-19 | イントレクソン・アクトバイオテイクス・エヌブイ | 1型糖尿病を処置するための組成物および方法 |
| US10858663B2 (en) | 2016-09-02 | 2020-12-08 | Intrexon Actobiotics N.V. | Genetically modified bacteria stably expressing IL-10 and insulin |
| KR102469701B1 (ko) * | 2016-09-13 | 2022-11-22 | 인트랙슨 액토바이오틱스 엔.브이. | 점막부착성 미생물 |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| US11541105B2 (en) | 2018-06-01 | 2023-01-03 | The Research Foundation For The State University Of New York | Compositions and methods for disrupting biofilm formation and maintenance |
| GB201906775D0 (en) * | 2019-05-14 | 2019-06-26 | Res & Innovation Uk | Synthetic genome |
| CA3156035A1 (en) | 2019-09-27 | 2021-04-01 | Intrexon Actobiotics Nv D/B/A Precigen Actobio | Treatment of celiac disease |
| WO2024003873A1 (en) | 2022-06-30 | 2024-01-04 | Intrexon Actobiotics Nv D/B/A Precigen Actobio | Single variable domain antibodies against tumor necrosis factor-alpha |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001062944A2 (en) * | 2000-02-24 | 2001-08-30 | Siga Pharmaceuticals, Inc. | Intergenic and intragenic integration sites for foreign gene expression in recombinant s. gordonii strains |
| US20100080774A1 (en) * | 2007-01-12 | 2010-04-01 | Actogenix N.V. | Lactococcus promoters and uses thereof |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB227835A (en) | 1924-01-15 | 1925-04-09 | Harry Odell | Improvements in feeding mechanism for embossing and other printing presses |
| JPS58116498A (ja) | 1981-12-28 | 1983-07-11 | Takeda Chem Ind Ltd | Il‐2をコードする新規伝令rnaの製造法 |
| EP0091539B2 (en) | 1982-03-31 | 1996-11-27 | Ajinomoto Co., Inc. | Gene coding for interleukin-2 polypeptide, recombinant DNA carrying said gene, cell lines possessing the recombinant DNA,and method for producing interleukin-2 using said cells |
| US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
| US4752585A (en) | 1985-12-17 | 1988-06-21 | Cetus Corporation | Oxidation-resistant muteins |
| JPH01196296A (ja) * | 1988-01-29 | 1989-08-08 | Toray Ind Inc | 動物細胞用発現ベクター |
| US4919918A (en) | 1988-03-14 | 1990-04-24 | Spectrum Consumer Products Co., Inc. | Non-alcoholic mouthwash |
| US5972685A (en) | 1988-07-21 | 1999-10-26 | Iowa State University Research Foundation, Inc. | Oral administration of coprostanol producing microorganisms to humans to decrease plasma cholesterol concentration |
| GB9006400D0 (en) | 1990-03-22 | 1990-05-23 | Ciba Geigy Ag | Bacterial vectors |
| WO1992014837A1 (en) | 1991-02-14 | 1992-09-03 | The General Hospital Corporation | Intestinal trefoil proteins |
| US6221840B1 (en) | 1991-02-14 | 2001-04-24 | The General Hospital Corporation | Intestinal trefoil proteins |
| US6277969B1 (en) | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
| GB9126306D0 (en) | 1991-12-11 | 1992-02-12 | Unilever Plc | Mouthwash compositions |
| EP0628083A1 (en) | 1992-02-27 | 1994-12-14 | Microbial Technics Limited | Heterologous gene expression in lactococcus, and the expression products therefrom |
| US5223285A (en) | 1992-03-31 | 1993-06-29 | Abbott Laboratories | Nutritional product for pulmonary patients |
| EP0569604A1 (en) | 1992-04-07 | 1993-11-18 | Societe Des Produits Nestle S.A. | Integrative gene-expression in Streptococcus salivarius ssp.thermophilus |
| US5229109A (en) | 1992-04-14 | 1993-07-20 | Board Of Regents, The University Of Texas System | Low toxicity interleukin-2 analogues for use in immunotherapy |
| US5700782A (en) | 1993-05-28 | 1997-12-23 | Abbott Laboratories | Enteral nutritional product |
| WO1996032486A1 (en) | 1995-04-11 | 1996-10-17 | Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno | Method for the construction of vectors for lactic acid bacteria like lactobacillus such that the bacteria can efficiently express, secrete and display proteins at the surface |
| US5695746A (en) | 1995-07-28 | 1997-12-09 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Liquid dentifrice with mouthwash fresh taste |
| GB9521568D0 (en) | 1995-10-20 | 1995-12-20 | Lynxvale Ltd | Delivery of biologically active polypeptides |
| US6348187B1 (en) | 1996-01-24 | 2002-02-19 | Warner-Lambert Company | Peroxide/essential oils containing mouthwash compositions and two-part mouthwash systems |
| GB9611364D0 (en) | 1996-05-31 | 1996-08-07 | Smithkline Beecham Plc | Composition |
| ES2197364T3 (es) | 1996-09-18 | 2004-01-01 | Erling Johansen | Baño bucal comprendiendo iones de calcio y fosfato en solucion sobresaturada. |
| US5869118A (en) | 1996-11-13 | 1999-02-09 | Abbott Laboratories | Gellan gum to improve physical stability of liquid nutritional products |
| US6171611B1 (en) | 1997-11-12 | 2001-01-09 | Dante J. Picciano | Iodine-containing nasal moisturizing saline and mouthwash solutions |
| US5897872A (en) | 1997-11-12 | 1999-04-27 | Picciano; Dante J. | Iodine-containing nasal moisturizing saline solution |
| WO2000018377A1 (en) | 1998-09-28 | 2000-04-06 | Warner-Lambert Company | Enteric and colonic delivery using hpmc capsules |
| WO2000022909A2 (en) | 1998-10-19 | 2000-04-27 | Biotech Australia Pty. Limited | Systems for oral delivery |
| EP1123314B1 (en) | 1998-10-20 | 2004-02-18 | Vlaams Interuniversitair Instituut voor Biotechnologie vzw. | Use of a cytokine-producing lactococcus strain to treat colitis |
| CA2378143A1 (en) | 1999-06-30 | 2001-01-11 | Societe Des Produits Nestle S.A. | The lactose operon of lactobacillus delbrueckii and its use for controlling gene transcription and/or expression in bacterial cells |
| ES2272311T3 (es) | 1999-07-05 | 2007-05-01 | Vlaams Interuniversitair Instituut Voor Biotechnologie | Suministro de peptidos trebol. |
| US7029842B2 (en) * | 2000-04-07 | 2006-04-18 | Novozymes A/S | Signal sequence trapping |
| GB0013810D0 (en) | 2000-06-06 | 2000-07-26 | Celltech Chiroscience Ltd | Biological products |
| CA2446776C (en) | 2001-05-03 | 2011-07-12 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Self-containing lactococcus strain |
| EP1319410A1 (en) * | 2001-12-11 | 2003-06-18 | Société des Produits Nestlé S.A. | Use of micro-organisms for a directed delivery of substances to specific parts of the gut |
| AU2003247881A1 (en) | 2002-07-08 | 2004-01-23 | Joe S. Wilkins Jr. | Antibacterial formulations |
| AU2003298291A1 (en) | 2002-11-15 | 2004-06-15 | Universiteit Gent | Self-containing lactobacillus strain |
| WO2004069177A2 (en) | 2003-01-31 | 2004-08-19 | The Trustees Of The University Of Pennsylvania | Methods for modulating an inflammatory response |
| EP1493816A1 (en) * | 2003-07-02 | 2005-01-05 | Friesland Brands B.V. | Methods and means for regulating gene expression |
| WO2005007121A2 (en) | 2003-07-18 | 2005-01-27 | Massachusetts Institute Of Technology | Mutant interleukin-2(il-2) polypeptides |
| CA2551644C (en) | 2003-12-24 | 2014-03-04 | Cerus Corporation | Recombinant nucleic acid molecules encoding fusion proteins comprising antigens and bacterial secretory signal polypeptides, expression cassettes, and bacteria, and methods of usethereof |
| US7842289B2 (en) * | 2003-12-24 | 2010-11-30 | Aduro Biotech | Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof |
| KR20070003934A (ko) | 2004-03-05 | 2007-01-05 | 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 | 치료제의 환자 내약성을 예측하기 위한 시험관 내 테스트시스템 |
| US7495092B2 (en) * | 2005-01-14 | 2009-02-24 | North Carolina State University | Compositions comprising promoter sequences and methods of use |
| US7764366B2 (en) | 2006-07-11 | 2010-07-27 | Besi North America, Inc. | Robotic die sorter with optical inspection system |
| JP2009544679A (ja) * | 2006-07-25 | 2009-12-17 | ザ ユニヴァーシティー コート オブ ザ ユニヴァーシティー オブ ダンディー | 異常な細胞増殖に関連する疾患の治療におけるレチノイド及び小分子のNrf2アンタゴニストとしての使用 |
| ES2425385T3 (es) | 2009-04-30 | 2013-10-15 | Actogenix N.V. | Crioprotectores para la liofilización de las bacterias de ácido láctico |
| CN105440123B (zh) | 2011-02-10 | 2020-10-09 | 罗切格利卡特公司 | 突变体白介素-2多肽 |
| US9669071B2 (en) | 2011-03-11 | 2017-06-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for stimulating T lymphocytes with IL-2 |
| EP2714912B1 (en) | 2011-06-01 | 2018-05-02 | Intrexon Actobiotics NV | Polycistronic expression system for bacteria |
| EP2753362A4 (en) | 2011-09-08 | 2015-04-15 | Univ Florida | MATERIALS AND METHOD FOR MODULATING IMMUNE SYSTEM REACTIONS |
| JP7292877B2 (ja) | 2016-01-14 | 2023-06-19 | イントレクソン・アクトバイオテイクス・エヌブイ | 1型糖尿病を処置するための組成物および方法 |
-
2012
- 2012-06-01 EP EP12729396.7A patent/EP2714912B1/en active Active
- 2012-06-01 KR KR1020137033153A patent/KR102066292B1/ko not_active Expired - Fee Related
- 2012-06-01 AU AU2012264589A patent/AU2012264589B2/en not_active Ceased
- 2012-06-01 CN CN201280026763.2A patent/CN103562390B/zh not_active Expired - Fee Related
- 2012-06-01 DK DK12729396.7T patent/DK2714912T3/en active
- 2012-06-01 HU HUE12729396A patent/HUE039577T2/hu unknown
- 2012-06-01 WO PCT/EP2012/060431 patent/WO2012164083A1/en not_active Ceased
- 2012-06-01 CA CA2837634A patent/CA2837634C/en active Active
- 2012-06-01 CN CN201710467009.7A patent/CN107267546B/zh not_active Expired - Fee Related
- 2012-06-01 EP EP18163611.9A patent/EP3360967B1/en active Active
- 2012-06-01 RU RU2013157300A patent/RU2644346C2/ru active
- 2012-06-01 CA CA3136084A patent/CA3136084A1/en not_active Abandoned
- 2012-06-01 US US14/122,545 patent/US9920324B2/en active Active
- 2012-06-01 BR BR112013030824A patent/BR112013030824A8/pt not_active IP Right Cessation
- 2012-06-01 RU RU2018102374A patent/RU2766157C2/ru active
- 2012-06-01 ES ES12729396.7T patent/ES2676877T3/es active Active
- 2012-06-01 JP JP2014513212A patent/JP6175428B2/ja not_active Expired - Fee Related
-
2017
- 2017-05-09 JP JP2017093388A patent/JP6867866B2/ja active Active
- 2017-05-16 AU AU2017203281A patent/AU2017203281B2/en not_active Ceased
-
2018
- 2018-02-15 US US15/897,427 patent/US10988770B2/en active Active
-
2020
- 2020-12-04 US US17/112,611 patent/US20210163961A1/en not_active Abandoned
-
2021
- 2021-02-02 JP JP2021015026A patent/JP2021097671A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001062944A2 (en) * | 2000-02-24 | 2001-08-30 | Siga Pharmaceuticals, Inc. | Intergenic and intragenic integration sites for foreign gene expression in recombinant s. gordonii strains |
| US20100080774A1 (en) * | 2007-01-12 | 2010-04-01 | Actogenix N.V. | Lactococcus promoters and uses thereof |
Non-Patent Citations (4)
| Title |
|---|
| Control of the Arabinose Regulon in Bacillus subtilis by AraR In Vivo: Crucial Roles of Operators, Cooperativity, and DNA Looping;LUI´S JAIME MOTA 等;《JOURNAL OF BACTERIOLOGY》;20010731;第183卷(第14期);第4194页左栏第2段,第4193页表2 * |
| Gene replacement in Staphylococcus carnosus and Staphylococcus xylosus.;Brückner R.;《FEMS Microbiol Lett.》;19970601;第151卷(第1期);1-8 * |
| Influence of Tn917 Insertion on Transcription of the icaADBC Operon in Six Biofilm-Negative Transposon Mutants of Staphylococcus epidermidis;Sabine Dobinsky 等;《Plasmid》;20020131;第47卷(第1期);10-17 * |
| Production systems for recombinant antibodies;Thomas Schirrmann 等;《Frontiers in Bioscience》;20080501;正文第4页第2段和第9页第1段 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10988770B2 (en) | Polycistronic expression system for bacteria | |
| CN101605900B (zh) | 乳球菌启动子和其用途 | |
| CA2787787A1 (en) | Transformation plasmid | |
| Wells et al. | Progress in the development of mucosal vaccines based on Lactococcus lactis | |
| HK1244033B (en) | Polycistronic expression system for bacteria | |
| HK1257050B (en) | Polycistronic expression system for bacteria | |
| Américo et al. | Genetically modified lactic acid bacteria in food and beverages: Safety concerns for industry and clinical use | |
| Chen et al. | Genetic operation system of lactic acid bacteria and its applications | |
| Remaut et al. | Clinical potential of Lactococcus lactis mediated delivery of human interleukin-10 and trefoil factors | |
| CN121532433A (zh) | 降低肿瘤内中性粒细胞水平的抗肿瘤细菌 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: Belgium F Wieland Applicant after: INTREXON ACTOBIOTICS N.V. Address before: Belgium F Wieland Applicant before: ACTOGENIX N.V. |
|
| COR | Change of bibliographic data | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20170718 |